Kristen M. Smith

Kristen M. Smith

Auto-generated profile, based on publicly available information

Kristen M. Smith

18Amgen Inc., South San Francisco, California

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2004 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
KFKarl J. L. Fernandes
Karl J. L. Fernandes
IMIan A. McKenzie
Ian A. McKenzie
PMPleasantine Mill
Pleasantine Mill
KSKristen M. Smith
Kristen M. Smith
MAMahnaz Akhavan
Mahnaz Akhavan
FMFreda D. Miller
Freda D. Miller

1 March 2013 in Cell Stem Cell
Verified
Journal Article
Closed access
DGDaniel J. Goff
Daniel J. Goff
ARAngela Court Recart
Angela Court Recart
ASAnil Sadarangani
Anil Sadarangani
HCHye-Jung Chun
Hye-Jung Chun
CBChristian L. Barrett
Christian L. Barrett
CJCatriona H.M. Jamieson
Catriona H.M. Jamieson

1 December 2007 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LHLoen M. Hansford
Loen M. Hansford
AMAmy E. McKee
Amy E. McKee
LZLibo Zhang
Libo Zhang
RGRani E. George
Rani E. George
JGJ. Ted Gerstle
J. Ted Gerstle
DKDavid R. Kaplan
David R. Kaplan
Neuroblastoma is a heterogeneous pediatric tumor thought to arise from the embryonic neural crest. Identification of the cell responsible for propagating neuroblastomas is essential to understanding this often recurrent, rapidly progressing disease. We have isolated and characterized putative tumor-initiating cells from 16 tumors and bone marrow metastases from patients in all neuroblastoma risk groups. Dissociated cells from tumors or bone marrow grew as spheres in conditions used to culture neural crest stem cells, were capable of self-renewal, and exhibited chromosomal aberrations typical of neuroblastoma. Primary spheres from all tumor risk groups differentiated under neurogenic conditions to form neurons. Tumor spheres from low-risk tumors frequently formed large neuronal networks, whereas those from high-risk tumors rarely did. As few as 10 passaged tumor sphere cells from aggressive neuroblastoma injected orthotopically into severe combined immunodeficient/Beige mice formed large neuroblastoma tumors that metastasized to liver, spleen, contralateral adrenal and kidney, and lung. Furthermore, highly tumorigenic tumor spheres were isolated from the bone marrow of patients in clinical remission, suggesting that this population of cells may predict clinical behavior and serve as a biomarker for minimal residual disease in high-risk patients. Our data indicate that high-risk neuroblastoma contains a cell with cancer stem cell properties that is enriched in tumor-initiating capacity. These cells may serve as a model system to identify the molecular determinants of neuroblastoma and to develop new therapeutic strategies for this tumor. [Cancer Res 2007;67(23):11234–43]

1 July 2003 in Molecular Cell
Verified
Journal Article
Closed access
KSKristen M. Smith
Kristen M. Smith
RYRinat Yacobi
Rinat Yacobi
RERichard A. Van Etten
Richard A. Van Etten

20 October 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
WKWilliam K Kelly
William K Kelly
DDDaniel C. Danila
Daniel C. Danila
CLChia-Chi Lin
Chia-Chi Lin
JLJae Lyun Lee
Jae Lyun Lee
NMNobuaki Matsubara
Nobuaki Matsubara
LALeonard J. Appleman
Leonard J. Appleman
Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)–targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such as those in advanced prostate cancer. This first-in-human study reports monotherapy dose exploration for patients with metastatic castration-resistant prostate cancer (mCRPC), primarily taxane pretreated. Ninety-seven patients received ≥1 intravenous dose ranging from 0.001 to 2.0 mg weekly or every 2 weeks. MTD was identified as 1.5 mg i.v. weekly via a 3-step dose. The most common treatment-related adverse events were cytokine release syndrome (CRS; 72%), fatigue (45%), and myalgia (34%). CRS occurred primarily during cycle 1 and improved with premedication and step dosing. Prostate-specific antigen (PSA) and RECIST responses across cohorts were encouraging [49% PSA50; 24% objective response rate (ORR)], with greater frequency at target doses ≥0.75 mg (59% PSA50; 41% ORR). Xaluritamig is a novel immunotherapy for prostate cancer that has shown encouraging results supporting further development.Significance: Xaluritamig demonstrated encouraging responses (PSA and RECIST) compared with historical established treatments for patients with late-line mCRPC. This study provides proof of concept for T-cell engagers as a potential treatment for prostate cancer, validates STEAP1 as a target, and supports further clinical investigation of xaluritamig in prostate cancer.See related commentary by Hage Chehade et al., p. 20.See related article by Nolan-Stevaux et al., p. 90.This article is featured in Selected Articles from This Issue, p. 5

1 May 2009 in Neoplasia
Verified
Journal Article
Open access
PDF file
LZLibo Zhang
Libo Zhang
KSKristen M. Smith
Kristen M. Smith
ACAmy Lee Chong
Amy Lee Chong
DSDiana Stempak
Diana Stempak
HYHerman Yeger
Herman Yeger
SBSylvain Baruchel
Sylvain Baruchel
Neoplasia publishes the results of novel investigations in all areas of oncology research.